The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Clinical trials involving frequent, standardized monitoring of the international normalized ratio (INR) demonstrated that a short course of low-molecular-weight-heparin (LMWH) can successfully bridge patients to oral anticoagulation. However, rigidly performed INR testing is often not feasible in the outpatient setting in actual clinical practice. The purpose of this study was to determine if the anticoagulation results of clinical trials of LMWH bridging therapy are also achieved in a single-center clinical practice setting.
We conducted a retrospective analysis of 100 patients initiating warfarin while receiving LMWH under the care of a university-based anticoagulation management service.
Mean patient age was 56.1 ± 16.3 years. The commonest indications for anticoagulation were venous thrombosis (57%) and atrial fibrillation (25%). Mean initial warfarin dose was 5.1 ± 1.8 mg/day; 30% of patients received antiplatelet therapy. The mean total duration of LMWH therapy was 12.0 ± 8.2 days, of which 9.8 ± 8.0 days (median 7.5 days; interquartile range 4.3–13.0 days) occurred in the outpatient setting. Forty-one percent of patients received outpatient LMWH for < 7 days, 40% for 7–14 days, and 19% for > 14 days. A mean of 3.9 ± 2.0 INRs were performed during LMWH therapy. Complications included 11 minor and 1 major bleeding episodes and 1 thrombotic event.
The duration of LMWH bridging therapy in practice may be significantly greater than previously reported in clinical trials, and the incidence of patients requiring prolonged (>14 days) LMWH therapy is relatively high. Outpatient LMWH as employed in clinical practice safely bridges patients to oral anticoagulation. Strategies to shorten the duration of LMWH therapy are needed and are likely to improve clinical outcomes and reduce health care expenses.
In prospective clinical trials low-molecular-weight-heparin (LMWH) has proven effective in transitioning patients with venous thromboembolic disease to therapeutic warfarin anticoagulation. However, it is unknown if the anticoagulation results obtained in these trials, which involved rigidly performed anticoagulation monitoring, are achieved in standard clinical practice involving patients with a variety of indications for anticoagulation. We conducted a retrospective analysis of 100 patients initiating warfarin while receiving LMWH under the management of a university-based anticoagulation management service. The mean total duration of LMWH therapy was 12.0 ± 8.2 days, of which 9.8 ± 8.0 days (median 7.5 days; interquartile range 4.3–13.0 days) occurred in the outpatient setting. Forty-one percent of patients received outpatient LMWH for <7 days, 40% for 7–14 days, and 19% for >14 days. We conclude that the duration of LMWH bridging therapy in practice may be significantly greater than previously reported in clinical trials, and the incidence of patients requiring prolonged (>14 days) LMWH therapy is relatively high.
- Dunn A, Bioh D, Beran M, Capasso M, Siu A (2004) Effect of intravenous heparin administration on duration of hospitalization. Mayo Clin Proc 79:159–163
- Spyropoulos AC (2005) Bridging of oral anticoagulation therapy for invasive procedures. Curr Hematol Rep 4:405–413
- Douketis JD, Johnson JA, Turpie AG (2004) Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 164:1319–26 CrossRef
- Levin M, Gent M, Hirsh J, et al (1996) A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Eng J Med 334:677–681 CrossRef
- Koopman MMW, Prandoni P, Piovella F, et al (1996) Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Eng J Med 334:682–687 CrossRef
- The Columbus Investigators (1997) Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Eng J Med 337:657–662 CrossRef
- Kim MH, Decena BF, Bruckman D, Eagle KA (2003) Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation. Am Heart J 145:665–669 CrossRef
- Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J (2003) Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart 89:527–530 CrossRef
- Kovacs MJ, Rodger M, Anderson DR, et al (2003) Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. Ann Intern Med 138:714–719
- Crowther MA, Ginsberg JB, Kearon C, et al (1999) A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 159:46–48 CrossRef
- Simonneau G, Sors H, Charbonnier B, et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group N Eng J Med 337:663–669
- Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J (1997) Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 126:133–136
- Fennerty A, Dolben J, Backhouse G, Bentley DP, Campbell IA, Routledge PA (1984) Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J Research Ed 288:1268–1270
- Deitcher SR (2004) Undue extension of hospital stay associated with anticoagulation. Mayo Clin Proc 79:157–158 CrossRef
- Ansell JE (2003) The perioperative management of warfarin therapy. Arch Intern Med 163:881–883 CrossRef
- Ansell JE, Hughes R (1996) Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J 132:1095–100 CrossRef
- Rieder MJ, Reiner AP, Gage BF, et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285–2293 CrossRef
- Sanderson S, Emery J, Higgins J (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7:97–104 CrossRef
- The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials
Journal of Thrombosis and Thrombolysis
Volume 23, Issue 2 , pp 107-113
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
- 2. Department of Internal Medicine, University of Missouri, One Hospital Drive, MC314, DC095.00, Columbia, MO, 65212, USA